halothane   Click here for help

GtoPdb Ligand ID: 2401

Synonyms: Fluothane®
Approved drug
halothane is an approved drug (FDA (1958))
Compound class: Synthetic organic
Comment: Halothane is a volatile anaesthetic which causes rapid anaesthesia, but requires use of additional nitrous oxide and/or neuromuscular blocking agents to be fully effective.
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 0
Hydrogen bond donors 0
Rotatable bonds 1
Topological polar surface area 0
Molecular weight 195.89
XLogP 3.16
No. Lipinski's rules broken 0
SMILES / InChI / InChIKey
Click here for help
Canonical SMILES ClC(C(F)(F)F)Br
Isomeric SMILES ClC(C(F)(F)F)Br
InChI InChI=1S/C2HBrClF3/c3-1(4)2(5,6)7/h1H
InChI Key BCQZXOMGPXTTIC-UHFFFAOYSA-N
Bioactivity Comments
Halothane potentiates human K2P9.1 (TASK-3) activity in vitro [7].[10].
Selectivity at ion channels
Key to terms and symbols Click column headers to sort
Target Sp. Type Action Value Parameter Concentration range (M) Reference
Kv2.1 Rn Channel blocker - 3.5 pEC50 - 4
pEC50 3.5 [4]
K2P3.1 Rn Activator Positive 3.0 pEC50 1x10-3 9,11
pEC50 3.0 (EC50 1x10-3 M) Conc range: 1x10-3 M studied at 1-10 mM [9,11]
Kir3.2 N/A Gating inhibitor Antagonist 4.2 pIC50 - 12
pIC50 4.2 [12]
Voltage: -70.0 mV
K2P5.1 Hs Activator - 3.7 pIC50 1x10-4 - 1x10-3 2
pIC50 3.7 Conc range: 1x10-4 - 1x10-3 M [2]
TRPM3 Hs Channel blocker Antagonist 3.3 pIC50 - 3
pIC50 3.3 (IC50 5.2x10-4 M) [3]
K2P2.1 Hs Activator - - - - 8
studied at 1-5 mM [8]
K2P3.1 Hs Activator - - - - 5
studied at 1-10 mM [5]
K2P9.1 Primary target of this compound Hs Activator - - - - 10
studied at 1-5 mM [10]
K2P10.1 Primary target of this compound Hs Activator - - - - 6
studied at 1-5 mM [6]
K2P12.1 Hs Inhibitor - - - - 1
[1]
K2P13.1 Hs Inhibitor - - - - 1
studied at ~5 mM [1]
Ligand mentioned in the following text fields